Dendritic cells activation is associated with sustained virological response to telaprevir treatment of HCV-infected patients

Research output: Contribution to journalArticle

Abstract

First anti-HCV treatments, that include protease inhibitors in conjunction with IFN-α and Ribavirin, increase the sustained virological response (SVR) up to 80% in patients infected with HCV genotype 1. The effects of triple therapies on dendritic cell (DC) compartment have not been investigated. In this study we evaluated the effect of telaprevir-based triple therapy on DC phenotype and function, and their possible association with treatment outcome. HCV+ patients eligible for telaprevir-based therapy were enrolled, and circulating DC frequency, phenotype, and function were evaluated by flow-cytometry. The antiviral activity of plasmacytoid DC was also tested. In SVR patients, myeloid DC frequency transiently decreased, and returned to baseline level when telaprevir was stopped. Moreover, an up-regulation of CD80 and CD86 on mDC was observed in SVR patients as well as an improvement of IFN-α production by plasmacytoid DC, able to inhibit in vitro HCV replication.

Original languageEnglish
Pages (from-to)82-90
Number of pages9
JournalClinical Immunology
Volume183
DOIs
Publication statusPublished - Oct 1 2017

Fingerprint

Dendritic Cells
Therapeutics
Phenotype
Ribavirin
Myeloid Cells
Protease Inhibitors
Antiviral Agents
telaprevir
Flow Cytometry
Up-Regulation
Genotype

Keywords

  • Dendritic cells
  • Directly acting antivirals
  • HCV
  • IFN-α
  • T cells

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

@article{75d88752b87d4bd78fcd66073adf7d83,
title = "Dendritic cells activation is associated with sustained virological response to telaprevir treatment of HCV-infected patients",
abstract = "First anti-HCV treatments, that include protease inhibitors in conjunction with IFN-α and Ribavirin, increase the sustained virological response (SVR) up to 80{\%} in patients infected with HCV genotype 1. The effects of triple therapies on dendritic cell (DC) compartment have not been investigated. In this study we evaluated the effect of telaprevir-based triple therapy on DC phenotype and function, and their possible association with treatment outcome. HCV+ patients eligible for telaprevir-based therapy were enrolled, and circulating DC frequency, phenotype, and function were evaluated by flow-cytometry. The antiviral activity of plasmacytoid DC was also tested. In SVR patients, myeloid DC frequency transiently decreased, and returned to baseline level when telaprevir was stopped. Moreover, an up-regulation of CD80 and CD86 on mDC was observed in SVR patients as well as an improvement of IFN-α production by plasmacytoid DC, able to inhibit in vitro HCV replication.",
keywords = "Dendritic cells, Directly acting antivirals, HCV, IFN-α, T cells",
author = "Alessandra Sacchi and Nicola Tumino and Federica Turchi and Giulia Refolo and Fimia, {Gian Maria} and Fabiola Ciccosanti and Marzia Montalbano and Raffaella Lionetti and Chiara Taibi and Gianpiero D'Offizi and Rita Casetti and Veronica Bordoni and Eleonora Cimini and Federico Martini and Chiara Agrati",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/j.clim.2017.07.017",
language = "English",
volume = "183",
pages = "82--90",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Dendritic cells activation is associated with sustained virological response to telaprevir treatment of HCV-infected patients

AU - Sacchi, Alessandra

AU - Tumino, Nicola

AU - Turchi, Federica

AU - Refolo, Giulia

AU - Fimia, Gian Maria

AU - Ciccosanti, Fabiola

AU - Montalbano, Marzia

AU - Lionetti, Raffaella

AU - Taibi, Chiara

AU - D'Offizi, Gianpiero

AU - Casetti, Rita

AU - Bordoni, Veronica

AU - Cimini, Eleonora

AU - Martini, Federico

AU - Agrati, Chiara

PY - 2017/10/1

Y1 - 2017/10/1

N2 - First anti-HCV treatments, that include protease inhibitors in conjunction with IFN-α and Ribavirin, increase the sustained virological response (SVR) up to 80% in patients infected with HCV genotype 1. The effects of triple therapies on dendritic cell (DC) compartment have not been investigated. In this study we evaluated the effect of telaprevir-based triple therapy on DC phenotype and function, and their possible association with treatment outcome. HCV+ patients eligible for telaprevir-based therapy were enrolled, and circulating DC frequency, phenotype, and function were evaluated by flow-cytometry. The antiviral activity of plasmacytoid DC was also tested. In SVR patients, myeloid DC frequency transiently decreased, and returned to baseline level when telaprevir was stopped. Moreover, an up-regulation of CD80 and CD86 on mDC was observed in SVR patients as well as an improvement of IFN-α production by plasmacytoid DC, able to inhibit in vitro HCV replication.

AB - First anti-HCV treatments, that include protease inhibitors in conjunction with IFN-α and Ribavirin, increase the sustained virological response (SVR) up to 80% in patients infected with HCV genotype 1. The effects of triple therapies on dendritic cell (DC) compartment have not been investigated. In this study we evaluated the effect of telaprevir-based triple therapy on DC phenotype and function, and their possible association with treatment outcome. HCV+ patients eligible for telaprevir-based therapy were enrolled, and circulating DC frequency, phenotype, and function were evaluated by flow-cytometry. The antiviral activity of plasmacytoid DC was also tested. In SVR patients, myeloid DC frequency transiently decreased, and returned to baseline level when telaprevir was stopped. Moreover, an up-regulation of CD80 and CD86 on mDC was observed in SVR patients as well as an improvement of IFN-α production by plasmacytoid DC, able to inhibit in vitro HCV replication.

KW - Dendritic cells

KW - Directly acting antivirals

KW - HCV

KW - IFN-α

KW - T cells

UR - http://www.scopus.com/inward/record.url?scp=85026806952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026806952&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2017.07.017

DO - 10.1016/j.clim.2017.07.017

M3 - Article

C2 - 28736275

AN - SCOPUS:85026806952

VL - 183

SP - 82

EP - 90

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

ER -